Helsinn Healthcare SA
https://www.helsinn.com/public/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Helsinn Healthcare SA
Can Roche’s Phesgo Mirror UK Adoption Trend in India?
Roche debuts ‘responsibly priced’ Phesgo in India. Will the dramatic reduction in treatment time for women with HER2 positive breast cancer and other benefits, including insurance coverage, trigger sharp shifts towards the subcutaneous fixed-dose combination of Perjeta and Herceptin?
Asia Deal Watch: Taiho Brings Cullinan Pearl Back In House
Taiho will pay Cullinan Oncology up to $405m for their joint venture and lead candidate for a form of lung cancer. Plus deals involving Zhaoke/Visus, AnGes/Eiger, Juniper/Helsinn, Peak Bio and more.
COVID-19 Relapses, Lack Of Omicron Data Complicate Paxlovid Case In India
A few cases of COVID-19 relapse have Twitter abuzz about the need for data on Paxlovid’s effectiveness, particularly against the Omicron variant and in vaccinated individuals. Despite regulatory approval in India, the drug has not yet been included in treatment guidelines and a debate on recommended dosage now complicates matters
Will Yabao Help Lupin’s Attempts To Scale The Great Wall?
With the Yabao partnership, Lupin builds on a toehold gained through the Foncoo tie-up as it attempts to scale the market behind the Great Wall of China. Scrip takes a look at possible approaches and potential of the partnership
Company Information
- Industry
- Distributors
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
- Nutraceuticals
- Specialty Pharmaceuticals
-
Drug Delivery
- Topical Delivery
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Sapphire Therapeutics
- Helsinn Pharmaceuticals Beijing Co. Ltd.